Severe exacerbation of asthma: A new side effect of interferon-α in patients with asthma and chronic hepatitis C

Mayo Clinic Proceedings

Volumn 74, Issue 4, 1999, Pages 367-370

  Bini, Edmund J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; PREDNISONE; RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; ASTHMA; CASE REPORT; FATIGUE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INSOMNIA; LUNG COMPLICATION; MALE;

EID: 0032963010     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.4.367     Document Type: Article

References (34)

1. Davis GL, Baiart LA, Schiff ER, Lindsay K, Bodenheimer HC 1t, Perrillo RP, et al (Hepatitis Interventional Therapy Group). Treatment of chronic hepatitis C with recombinant Interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989:321:1501-1506
2. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 1995;15:64-69
3. Bellary S, Smith DG, Bankes P, Harris A, Shayiq R, Black M. High dose interferon α-2b therapy for chronic hepatitis C: an open label study of the response and predictors of response. Am J Gastroenterol 1995:90:259-262
4. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778-789
5. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995:15:82-91
6. Reichard 0, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. Two-year biochemical, virological, and histologi-
7. cal follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-922
8. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al (Multicenter Study Group). A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N EnglJ Med 1995;332:1457-1462
9. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesei DW, Kumpel GR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991;266:1375-1383
10. Gutterman JU. Cytokine therapeutics: lessons from interferon a. Proc Natl Acad Sei USA 1994:91:1198-1205
11. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997:112:1017-1021
12. Sonnenblick M, Rosin A. Cardiotoxicity of interferon: a review of 44 cases. Chest 1991:99:557-561
13. Kamisako T, Adachi Y, Chihara J, Yamamoto T. Interstitial pneumonitis and interferon-alfa. BMJ 1993:306:896
14. Murata M, Nagai M, Bando S, Dobashi H, Takahara J. Emergence of acute interstitial pneumonia following high dose interferon a treatment in a case of chronic myelogenous leukemia. Intern Med 1993; 32:716-718
15. Yufu Y, Yamashita S, Nishimura J, Nawata H, Hirata J. Interstitial pneumonia caused by interferon-a in chronic myelogenous leukemia [letter]. Am J Hematol 1994;47:253
16. Hizawa N, Kojima J, Kojima T, Sukoh N, Yamaguchi E, Kawakami Y, et al. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern Med 1994:33:337341
17. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105:939-941
18. Moriya K, Yasuda K, Koike K, Ichinose Y, Yotsuyanagi H, Kurokawa K, et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994;29:514-517
19. Nouri K, Valor R, Rodriguez FM, Kerdel FA. Interferon alfa-induced interstitial pneumonitis in a patient with cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:269-270
20. Wolf Y, Haddad R, Jossipov J, Werbin N. Alpha-interferon induced severe pneumonitis [letter]. J Toxicol Clin Toxicol 1997;35:113-114
21. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612-613
22. Krasnowska M, Malolepszy J, Liebhart E. Interferon as a bronchospastic factor in patients with bronchial asthma. Pneumonol Alergol Pol 1992;60:22-25
23. Krasnowska M, Malolepszy J, Liebhart E, Inglot AD. Inhaled natural human interferon alpha induces bronchospastic reactions in asthmatics. Arch Immunol Ther Exp (Warsz) 1992:40:75-78
24. Goldstein RA, Paul WE, Metcalfe DD, Busse WW, Reece ER. Asthma. Ann Intern Med 1994:121:698-708
25. Kline JN, Hunninghake GW. T-lymphocyte dysregulation in asthma. Proc Soc Exp Biol Med 1994;207:243-253
26. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991;88:935942
27. Del Prête G. Human Thl and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 1992;47:450-455
28. Abehsira-Amar 0, Gibert M, Joliy M, Thèze J, Jankovic DL. IL-4 plays a dominant role in the differential development of Tho into Thl andTh2 cells. J Immunol 1992; 148:3820-3829
29. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant T -like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992:326:298-304
30. Corrigan CJ, Hamid Q, North J, Barkans J, Moqbel R, Durham S, et al. Peripheral blood CD4 but not CDS T-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy. Am J Respir Cell Mol Biol 1995:12:567-578
31. Barnes PJ. Immunomodulation as asthma therapy: where do we stand? Eur Respir J Suppl 1996;22:154s-159s
32. Corrigan CJ, Kay AB. CD4 T lymphocyte activation in acute severe asthma. Int Arch Allergy Appl Immunol 1991;94:270-271
33. Virchow JC Jr, Kroegel C, Walker C, Matthys H. Inflammatory determinants of asthma severity: mediator and cellular changes in bronchoalveolar lavage fluid of patients with severe asthma. J Allergy Clin Immunol 1996;98:S27-S33
34. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992;146:109-115